À¯¾Æ Ç÷°üÁ¾¿¡¼ Àú¿ë·® PropranololÀÇ »ç¿ë ÀûÀý¼º Æò°¡
Drug Use Evaluation of Low-dose Propranolol on Infantile Hemangioma
º´¿ø¾à»çȸÁö 2014³â 31±Ç 2È£ p.705 ~ p.712
¼Õ¸°(Son Rin) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
Á¤¾ÖÈñ(Jung Ae-Hee) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
Á¶ÀºÁ¤(Cho Eun-Jeong) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
ÀÌ¿ëÈ(Lee Yong-Hwa) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
ÀÌÇý¼÷(Lee Hye-Sook) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
±èÇâ¼÷(Kim Hyang-Suk) - ¼¿ï´ëÇб³º´¿ø ¾àÁ¦ºÎ
Abstract
Infantile hemangiomas (IH) are the most common benign tumor during childhood. The majority are self-resolving, however, 10% of patients require treatment. Researches on the efficacy of propranolol for IH have been reported outside of Korea since 2008. This study evaluated a low-dose propranolol use on IH based on its clinical efficacy and adverse event profiles. Total of 59 children, 3-year-old or younger, diagnosed IH and took propranolol as a maintenance dosage of 2 mg/kg/day between November 2009 and July 2011, were culled from Seoul National University Children¡¯s Hospital using electrolyte medical records retrospectively. For comparison, clinical photos were taken before, during and after treatment.
IH was predominantly presented in female (Male: Female=1:2.5), 39% of which occurred and was distinguished at birth (n=23). For the remains (n=36), 69% of children (n=25) occurred within a month. Location of the IH was as follows: face and neck (n=44), trunk (n=4), the limbs (n=6), multiples (n=5), respectively. Mean age of treatment initiation was 5-month-old (range 1.3-16) and the total duration of treatment was an average of 8 months (range 2.3-22). 22% of patients showed a rebound growth when the medication was discontinued and restarted propranolol, receiving relatively shorter courses; a mean of 4 months (range 1 week - 11 months). Based on the initial diagnosis, more than 50% of the reduction in the size of lesion was exhibited at 48 patients, followed by four with less reduction and no changes in seven. Total 59% of patients
(n=36) displayed improvement within a month such as a regression in size, softening in the lesion and faded in color. 22 patients experienced minor but reportable side effects to propranolol, including rash (n=8), gastro-esophageal reflux (n=7), hypotension (n=3), somnolence (n=2), and others (respiratory distress, n=1, hypothermia, n=1), respectively. In this study, the clinical efficacy of low-dose propranolol use on IH was confirmed. Due to the limited data from Seoul National University Children¡¯s Hospital, prospective studies with more patients are needed and the guideline for duration and dosage of propranolol should be further elaborated.
Å°¿öµå
Infantile hemangioma, Propranolol, Efficacy
KMID :
0869620140310020705
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)